Technologies


 

 

 

 

 

 

 

 

 


Surgical Implant Schematic

Image Courtesy of Ehrensberger et al. 

Technologies

Overview

Garwood received approval of its patent application on wound care. We have exclusive licensing agreements with the University at Buffalo’s technology for the eradication of biofilms on implants as well as its ion-sensitive pH sensor and cellular-level infrared (temperature) sensor technologies, covered by granted patents. The team members have developed and commercialized many other devices and have the in house competence to develop and launch leading edge products. 

Photo 1Design

Utilizing supercomputer modelling and rational product design, GMD is committed to improving existing form-factors, electro-stimulation treatments, monitoring and high-throughput data analysis. 

Wound Healing

Background: Nine million people in American suffer from chronic wounds. Others have trauma or surgical wounds. Electrical stimulation to increase the rate of healing is an established and proven methodology. Patients with slow to heal surgical incisions, diabetic ulcers, pressure ulcers and similar conditions that last over 30 days, frequently involve infection, pain and restrictions on activity. These have all been successfully treated with electrical stimulation, but currently, treatment requires expensive, heavy equipment with a power cord and clinician intervention. These constraints lead to artificially limited treatments, due to costs and reimbursement rates, which can lead to the impression that electrical stimulation is not fully effective.

GMD Solution: Our electronic bandage is patient-administered, and in the second generation, will offer the clinician the ability to remotely program the device, while monitoring the patient, and benefiting from having de-identified patient data analyzed by bioinformatics software, to improve protocols over time.

Triage remotely: The ability to remotely monitor the state of wound healing allows clinicians to respond more efficiently and provide targeted levels of care.

Orthopaedic Implant Infections: 20% failure to re-implant

Background: In America, orthopaedic implant infections rates average 2.4%. In 2020, knee and hip joint replacements will exceed 2,000,000 while implant infections in those joints alone are expected to be 50,000 or more, with 10,000 patients never having a successful revision surgery. Those 10,000 patients suffer one of several unappealing results: the loss of a limb, living with spacers, no joint at all or a fused joint for the balance of their lives. In some cases, the infection leads to death.

Procedure: Orthopaedic implant infections are very difficult to treat. Antibiotics are used, but some bacteria have developed resistance to an array of known pharmaceuticals. The bacteria form a bio-film on the implant that is difficult to break down. The vast majority of patients with a diagnosed peri-prosthetic implant infection will have the joint removed, bone debrided, antibiotic loaded spacer inserted, four weeks of IV antibiotics, and a six to eight week waiting period to be certain the infection is gone. Because the infection may have required the removal of bone and other tissue, successful replacement surgery is achieved in (only) approximately 80% of patients, after 4.2 months on average before the replacement orthopaedic implant operation can occur.

GMD Solution: Utilize a biofilm eradication technology licensed exclusively from the University at Buffalo. Ehrensberger et al have demonstrated using Cathodic Voltage Controlled Electrical Stimulation (CVCES) that the biofilm can be broken down such that bacteria is “visible” to the immune system, and susceptible to the drugs and the infection can be eradicated. Their studies have shown that the application of constant cathodic voltage of 1.8V to commercially pure titanium for one hour significantly reduces MRSA viability. The stimulation elicits antimicrobial activity against the bacteria on the implant and in surrounding bone tissue.  

Photo2